

Special Issue

miRNAs in Targeted Cancer Therapy

Message from the Guest Editor

miRNAs play important roles also in regulating and predicting resistance to cancer therapy. Moreover, the pleiotropic nature of miRNAs allows them to influence multiple genes and pathways simultaneously, offering a unique advantage over traditional single-target therapies, such as miRNA-based combination therapies alongside chemotherapeutic drugs, which have shown synergistic effects, overcoming drug resistance and reducing side effects. We are pleased to invite you to contribute to this Special Issue, aiming to highlight the roles of miRNAs specifically for cancer therapy. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: the role of miRNAs in cancer therapy, delivery of miRNAs for cancer therapy, mechanisms of miRNA therapeutics for any cancer type. I look forward to receiving your contributions.

Guest Editor

Dr. Mustafa Özen

1. Department of Medical Genetics, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye
2. Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA

Deadline for manuscript submissions

30 September 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/226360

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)